HRP980554A2 - 3-substituted tetrahydropyridopyrimidinon derivatives, their preparation and use - Google Patents
3-substituted tetrahydropyridopyrimidinon derivatives, their preparation and useInfo
- Publication number
- HRP980554A2 HRP980554A2 HR19747063.7A HRP980554A HRP980554A2 HR P980554 A2 HRP980554 A2 HR P980554A2 HR P980554 A HRP980554 A HR P980554A HR P980554 A2 HRP980554 A2 HR P980554A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- substituted
- branched
- unbranched
- unsubstituted
- Prior art date
Links
- -1 3-substituted tetrahydropyridopyrimidinon Chemical class 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 44
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 24
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 24
- 229940076279 serotonin Drugs 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 150000001923 cyclic compounds Chemical class 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims description 3
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 229910052786 argon Inorganic materials 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims description 2
- 125000006681 (C2-C10) alkylene group Chemical group 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000000697 serotonin reuptake Effects 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 238000002844 melting Methods 0.000 description 21
- 230000008018 melting Effects 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- 102000007527 Autoreceptors Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108010071131 Autoreceptors Proteins 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000003518 presynaptic effect Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PZFSNQTXBRIQQF-UHFFFAOYSA-N 4-naphthalen-1-yl-1,2,3,6-tetrahydropyridine Chemical compound C1NCCC(C=2C3=CC=CC=C3C=CC=2)=C1 PZFSNQTXBRIQQF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- SSSBLYQLIOQJSB-UHFFFAOYSA-N 4-naphthalen-1-ylpiperidine Chemical compound C1CNCCC1C1=CC=CC2=CC=CC=C12 SSSBLYQLIOQJSB-UHFFFAOYSA-N 0.000 description 2
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 description 2
- 102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 description 2
- PVNGDFHKRAIVTC-UHFFFAOYSA-N 6-benzyl-1,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one Chemical compound C1C=2C(=O)N=CNC=2CCN1CC1=CC=CC=C1 PVNGDFHKRAIVTC-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 101100149678 Caenorhabditis elegans snr-3 gene Proteins 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101150050738 HTR1B gene Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 239000004000 serotonin 1B antagonist Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- SWEGVUWSXJEPIF-UHFFFAOYSA-N tert-butyl 4-naphthalen-1-yl-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2C3=CC=CC=C3C=CC=2)=C1 SWEGVUWSXJEPIF-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- FHLXQXCQSUICIN-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[3,2-d]pyrimidine Chemical compound C1=CC=C2NCNCC2=N1 FHLXQXCQSUICIN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- VNICFCQJUVFULD-UHFFFAOYSA-N 1-(1-naphthalenyl)piperazine Chemical compound C1CNCCN1C1=CC=CC2=CC=CC=C12 VNICFCQJUVFULD-UHFFFAOYSA-N 0.000 description 1
- GJOBEWYDAQTKDU-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-4-yl)piperazine Chemical compound C=12CCCC2=CC=CC=1N1CCNCC1 GJOBEWYDAQTKDU-UHFFFAOYSA-N 0.000 description 1
- MUSOMUXTQGJZKD-UHFFFAOYSA-N 1-(2-chloroethyl)-4-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCN(CCCl)CC1 MUSOMUXTQGJZKD-UHFFFAOYSA-N 0.000 description 1
- CZTHNFFYQLEWJT-UHFFFAOYSA-N 1-(2-chloroethyl)-4-(3,4-dimethylphenyl)piperazine Chemical compound C1=C(C)C(C)=CC=C1N1CCN(CCCl)CC1 CZTHNFFYQLEWJT-UHFFFAOYSA-N 0.000 description 1
- MAIPOMCACBNHEI-UHFFFAOYSA-N 1-(2-chloroethyl)piperazine Chemical compound ClCCN1CCNCC1 MAIPOMCACBNHEI-UHFFFAOYSA-N 0.000 description 1
- OIZBMQFOSPOOIS-UHFFFAOYSA-N 1-(3-chloropropyl)-4-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCN(CCCCl)CC1 OIZBMQFOSPOOIS-UHFFFAOYSA-N 0.000 description 1
- QYHUWTWTZWQCJT-UHFFFAOYSA-N 1-(3-chloropropyl)-4-naphthalen-1-ylpiperazine Chemical compound C1CN(CCCCl)CCN1C1=CC=CC2=CC=CC=C12 QYHUWTWTZWQCJT-UHFFFAOYSA-N 0.000 description 1
- FBPPFIPXMJEJCU-UHFFFAOYSA-N 1-(5,6,7,8-tetrahydronaphthalen-1-yl)piperazine Chemical compound C1CCCC2=C1C=CC=C2N1CCNCC1 FBPPFIPXMJEJCU-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- MLXIGMYNOXFJAH-UHFFFAOYSA-N 1-chloro-4-piperazin-1-ylphthalazine Chemical compound C12=CC=CC=C2C(Cl)=NN=C1N1CCNCC1 MLXIGMYNOXFJAH-UHFFFAOYSA-N 0.000 description 1
- PWMNWKMSCLDPAG-UHFFFAOYSA-N 1-naphthalen-1-ylazepane Chemical compound C1CCCCCN1C1=CC=CC2=CC=CC=C12 PWMNWKMSCLDPAG-UHFFFAOYSA-N 0.000 description 1
- VNOBUFJWMNTPIS-UHFFFAOYSA-N 2-[4-(2-chloroethyl)piperazin-1-yl]pyrimidine Chemical compound C1CN(CCCl)CCN1C1=NC=CC=N1 VNOBUFJWMNTPIS-UHFFFAOYSA-N 0.000 description 1
- YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 1
- IMAWRJZYXYLGBL-UHFFFAOYSA-N 2-methoxy-1-phenylpiperazine Chemical compound COC1CNCCN1C1=CC=CC=C1 IMAWRJZYXYLGBL-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SCRBSGZBTHKAHU-UHFFFAOYSA-N 4-bromoisoquinoline Chemical compound C1=CC=C2C(Br)=CN=CC2=C1 SCRBSGZBTHKAHU-UHFFFAOYSA-N 0.000 description 1
- NIBZKHUIJGTBOX-UHFFFAOYSA-N 4-piperazin-1-ylisoquinoline Chemical compound C1CNCCN1C1=CN=CC2=CC=CC=C12 NIBZKHUIJGTBOX-UHFFFAOYSA-N 0.000 description 1
- KLTHGJYCURVMAK-UHFFFAOYSA-N 4-piperazin-1-ylquinazoline Chemical compound C1CNCCN1C1=NC=NC2=CC=CC=C12 KLTHGJYCURVMAK-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- SPXJZGXITAWLIO-UHFFFAOYSA-N 6-benzyl-3-(2-chloroethyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-one Chemical compound C1C=2C(=O)N(CCCl)C=NC=2CCN1CC1=CC=CC=C1 SPXJZGXITAWLIO-UHFFFAOYSA-N 0.000 description 1
- RYFHYPQWMRYOIM-UHFFFAOYSA-N 6-benzyl-3-[2-(4-isoquinolin-4-ylpiperazin-1-yl)ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-one Chemical compound C1CC=2N=CN(CCN3CCN(CC3)C=3C4=CC=CC=C4C=NC=3)C(=O)C=2CN1CC1=CC=CC=C1 RYFHYPQWMRYOIM-UHFFFAOYSA-N 0.000 description 1
- YXDZFOSTNBHDQZ-UHFFFAOYSA-N 6-benzyl-3-[2-(4-naphthalen-1-ylpiperazin-1-yl)ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-one Chemical compound C1CC=2N=CN(CCN3CCN(CC3)C=3C4=CC=CC=C4C=CC=3)C(=O)C=2CN1CC1=CC=CC=C1 YXDZFOSTNBHDQZ-UHFFFAOYSA-N 0.000 description 1
- LEACNBMPNIFUTQ-UHFFFAOYSA-N 6-benzyl-3-[2-(4-quinazolin-4-ylpiperazin-1-yl)ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-one Chemical compound C1CC=2N=CN(CCN3CCN(CC3)C=3C4=CC=CC=C4N=CN=3)C(=O)C=2CN1CC1=CC=CC=C1 LEACNBMPNIFUTQ-UHFFFAOYSA-N 0.000 description 1
- YGOFUUSDCBDTFQ-UHFFFAOYSA-N 6-benzyl-3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-one Chemical compound COC1=CC=CC=C1N1CCN(CCN2C(C=3CC(CC=4C=CC=CC=4)NCC=3N=C2)=O)CC1 YGOFUUSDCBDTFQ-UHFFFAOYSA-N 0.000 description 1
- KHFDQRBPPUWJCO-UHFFFAOYSA-N 6-benzyl-3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-one Chemical compound COC1=CC=CC=C1N1CCN(CCN2C(C=3CN(CC=4C=CC=CC=4)CCC=3N=C2)=O)CC1 KHFDQRBPPUWJCO-UHFFFAOYSA-N 0.000 description 1
- NDTZNBNFMXWWPK-UHFFFAOYSA-N 6-benzyl-3-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-one Chemical compound COC1=CC=CC=C1N1CCN(CC(O)CN2C(C=3CN(CC=4C=CC=CC=4)CCC=3N=C2)=O)CC1 NDTZNBNFMXWWPK-UHFFFAOYSA-N 0.000 description 1
- WMTKYCXDAWSDBX-UHFFFAOYSA-N 6-benzyl-3-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-one Chemical compound COC1=CC=CC=C1N1CCN(CCCN2C(C=3CC(CC=4C=CC=CC=4)NCC=3N=C2)=O)CC1 WMTKYCXDAWSDBX-UHFFFAOYSA-N 0.000 description 1
- JFXLRCFAXQRXCJ-UHFFFAOYSA-N 6-benzyl-3-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-one Chemical compound COC1=CC=CC=C1N1CCN(CCCN2C(C=3CN(CC=4C=CC=CC=4)CCC=3N=C2)=O)CC1 JFXLRCFAXQRXCJ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- ULMHMJAEGZPQRY-UHFFFAOYSA-N N-(tert-butoxycarbonyl)piperidin-2-one Chemical compound CC(C)(C)OC(=O)N1CCCCC1=O ULMHMJAEGZPQRY-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 230000001908 autoinhibitory effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- VIJMMQUAJQEELS-UHFFFAOYSA-N n,n-bis(ethenyl)ethenamine Chemical compound C=CN(C=C)C=C VIJMMQUAJQEELS-UHFFFAOYSA-N 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Structure And Mechanism Of Cameras (AREA)
Description
Predloženi izum odnosi se na derivate 3-supstituiranog tetrahidropiridopirimidinona, njihovo pripravljanje i upotrebu za proizvodnju aktivnih sastojaka lijekova.
Klasični antidepresanti i noviji selektivni inhibitori ponovnog uzimanja serotonina (SSRIs) razvijaju svoj učinak antidepresanta, između ostalog, inhibicijom aktivnog ponovnog uzimanja transmitera presinaptičke završetke živaca. Na nesreću, njihov antidepresantni učinak se uspostavlja najmanje tek tri tjedna nakon liječenja, i čak štoviše, pribl. 30% pacijenata je rezistentno prema terapiji.
Blokoda presinaptičkih serotonin autoreceptora se povisuje, poništavajući negativno vezanje, serotonin se oslobađa i time stvarna koncentracija transmitera u sinaptičkom procjepu. To povišenje koncentracije transmitera se smatra načelom antidepresantnog učinka. Taj mehanizam djelovanja rezlikuje se od ranije poznatih antidepresanata, koji aktiviraju oboje, presinaptičke i somatodendritičke autoreceptore, i zbog toga imaju za posljedicu odgođeno uspostavljanje djelovanja, samo nakon desenzitizacije tih autoreceptora. Izravna blokada autoreceptora premošćuje taj učinak.
Poznati su derivati opisani u JP 08027149 i JP 04054181.
Prema sadašnjem znanju, presinaptički autoreceptor serotonina je 5-HT1B podtip (Fink. Et al., Arch. Pharmacol. 352 (1995), 451). Njegova selektivna blokada s HT1B/D antagonistima povisuje oslobađanje serotonina u mozgu; G.W. Price et al., Behavioural Brain Research 73 (1996), 79-82; P.H. Hutson et al., Neuropharmacology Vol. 34, br. 4 (1995), 383-392.
Iznenađujuće, međutim, nakon sistemskog davanja, selektivni 5-HT1B antagonist GR 127 935 semnjuje oslobađanje serotonina u korteksu. Jedno objašnjenje može biti stimulacija somatodendritičkih 5-HT1B u području rafa oslobađanjem serotonina, koji inhibira brzinu zapaljenja serotonergnih neurona i stoga oslobađanje serotonina (M. Skingle et al., Neuropharmacology Vol. 34 br. 4 (1995), 377-382, 393-402).
Stoga je jedna strategija za premošćivanje autoinhibicijskih učinaka u serotonergnim područjima izvorno usmjerena na blokiranje presinaptičkih 5-HT1B receptora. Tu hipotezu podupiru opažanja da se učinak paroksetina na oslobađanje serotonina u leđnoj rafe jezgri štakora pojačava s 5-HT1B receptor antagonistom GR 127 935 (Davidson i Stamford, Neuroscience Lett., 188 (1995), 41).
Druga strategija uključuje blokadu obaju tipova autoreceptora, naime 5-HT1A receptora, da se pojačaju neuronski signali, i 5-HT1B receptora, da se poveća terminalno oslobađanje serotonina (Starkey i Skingle, Neuropharmacology 33 (3-4) (1994), 393).
5-HT1B/D antagonisti, sami ili povezani na antagonističku komponentu HT1B receptora, trebali bi stoga uzrokovati pojačano oslobađanje serotonina u mozgu i zbog toga se mogu korisno povezati s terapijom depresija i srodnih psiholoških poremećaja.
Sada je pronađeno da derivati 3-supstituiranog tetrahidropiridopirimidinona formule Ι
[image]
u kojoj
jedan od dva radikala X i Y je CH2, a drugi je NR1,
R1je vodik, razgranati ili nerazgranati C1-C6-alkil, CO-( C1-C4)-alkil, CO2tBu, CO-aril i radikal fenilalkil C1-C4 koji sa svoje strane može biti supstituiran na aromatskom sistemu s F, Cl, Br, J, C1-C4-alkilom, C1-C4-alkoksi, trifluormetilom, hidroksilom, amino, cijano ili nitro,
A je razgranati ili nerazgranati (C1-C10 )-alkilen ili ravan ili razgranati (C2-C10 )-alkilen koji sadrži najmanje jednu skupinu Z odabranu između O, S, NR2 , ciklopropila, CHOH, dvostruke ili trostruke veze,
R2je vodik ili C1-C4-alkil,
B je 1,4-piperidinilen, 1,2,3,6-tetrahidro-1,4-pridinilen, 1,4-piperazinilen ili odgovarajući ciklički spoj produljen s jednom metilenskom skupinom, pri čemu se povezivanje na A vrši preko dušikovog atoma skupine B, i
Ar je fenil koji nije supstituiran ili je supstituiran s razgranatim ili nerazgranatim (C1-C6)-alkilom, s razgranatim ili nerazgranatim O-(C1-C6)-alkilom, OH, F,CI, Br, J, trifluormetilom, NR2 2, CO2 R2, cijano ili fenilom, ili je tetralinil, indanil, fuzionirani aromatski sistemi kao naftil koji nije supstituiran ili je supstituiran sa (C1-C4)-alkilom ili O-(C1-C4)-alkilom, antril ili petero- ili šesteročlani aromatski heterocikl koji ima 1 ili 2 heteroatoma odabrana međusobno neovisno između O i N, koji također može biti fuzioniran na druge aromatske radikale,
i njihove soli s fiziološki podnošljivim kiselinama, imaju dragocjena farmakološka svojstva.
Posebno prednosni spojevi su oni u kojima
jedan od dva radikala X i Y je CH2, a drugi je NR1,
R1je vodik, razgranati ili nerazgranati C1-C4-alkil, CO-( C1-C4)-alkil, CO2tBu, COPh ili radikal fenilalkil C1-C2 koji sa svoje strane može biti supstituiran na aromatskom sistemu s F, CI, Br, J, C1-C4-alkilom, C1-C4-alkoksi, trifluormetilom, hidroksilom ili cijano,
A je razgranati ili nerazgranati (C2-C5)-alkilen ili (C2-C5)-alkilen koji sadrži skupinu Z odabranu između CHOH, ciklopropila, dvostruke ili trostruke veze,
B je 1,4-piperidinilen, 1,2,3,6-tetrahidro-1,4-pridinilen, 1,4-piperazinilen ili homopiperazinilen, pri čemu se povezivanje na A vrši preko dušikovog atoma B, i
Ar je fenil koji nije supstituiran ili je supstituiran s razgranatim ili nerazgranatim (C1-C6)-alkilom, s razgranatim ili nerazgranatim O-(C1-C6)-alkilom, F,CI, Br, J, trifluormetilom, NR2 2, CO2 R2, cijano ili fenilom, ili je tetralinil, indanil, fuzionirani aromatski sistemi kao naftil nije koji nije supstituiran ili je supstituiran sa (C1-C4)-alkilom ili O-(C1-C4)-alkilom, ili petero- ili šesteročlani aromatski heterocikl koji ima 1 ili 2 dušikova atoma, koji može biti fuzioniran na druge aromatske radikale.
Posebno prednosni spojevi formule Ι su oni koji su navedeni u trećem patentnom zahtjevu.
Spojevi formule Ι mogu imati jedno ili više središta asimetrije. Izum stoga uključuje ne samo racemate već također relevantne enantiomere i diastereomere. Izum također uključuje i dotične tautomerne oblike.
spojevi formule Ι mogu se proizvesti reakcijom spoja formule ΙΙ
[image]
u kojoj A, X i Y imaju gore navedena značenja, a Q je skupina koja se može odstraniti (npr. CI, Br, J, alkansulfoniloksi ili arilsulfoniloksi), sa spojem formule ΙΙΙ,
H-B-Ar ΙΙΙ
gdje B i Ar imaju gore navedena značenja, na sam po sebi poznat način, i pretvorbom na taj način dobivenog spoja u odgovarajuću adicijsku sol s fiziološki podnošljivom kiselinom. Slično može reagirati spoj formule ΙV
[image]
sa spojem formule V
Q-A-B-Ar V
na sam po sebi poznat način.
Druga varijanta sinteze uključuje povezivanje spoja formule VΙ
[image]
sa spojem formule ΙΙΙ reduktivnim aminiranjem, koje je poznato samo po sebi.
Spojevi formule ΙΙΙ mogu se sintetizirati
1. povezivanjem spoja formule VΙΙ
W-B1(VΙΙ)
u kojoj B1 je piperazin ili homopiperazin i W je vodik ili uobičajena amino zaštitna skupina (npr. Boc ili Cbz), sa spojem formule VΙΙΙ
P-Ar (VΙΙΙ)
u kojoj P je B (OH)2, SnR3, Otf, Br, Cl ili J i R je C1-C4-alkil, na poznat način; ili
2. povezivanjem spoja formule ΙΧ
W-B2-p1 (ΙΧ)
gdje B2 predstavlja 1,2,3,6-tetrahidro-1,4-piridinilen i odgovarajuće ciklički spojevi produljeni s jednom metilenskom skupinom, a p1 je CI, Br, J, SnR3, gdje R je C1-C4-alkil ili Otf sa spojem formule Χ
P-Ar (Χ)
gdje W, P i Ar imaju gore navedena značenja, i reakcije se provode poznatim postupcima koji su opisani , na primjer, u
S.L. Buchwald et al., J. Am. Chem. Soc. 1996, 118, 7215;
J. F. Hartwig et al., Tetrahedron Lett. 1995, 36, 3604;
J.K. Stille et al., Angew. Chem. 1986, 98, 504;
S.L. Buchwald et al., Angew Chem. 1995, 107, 1456 ili
J. F. Hartwig et al., J. Am. Chem. Soc. 1996, 118, 7217; ili
J. F. Hartwig et al., J. Org. Chem. 1997, 62, 1268;
S.L. Buchwald et al., J. Org. Chem. 1997, 62, 1264 i tamo citirana literatura; ili
S.L. Buchwald et al., J. Am. Chem. Soc. 1997, 119, 6054;
J.K. Stille et al., Angew. Chem. 1986, 98, 504; ili
J.K. Stille et al., J. Org. Chem. 1990, 55, 3014;
M. Pereyre et al., “Tin in Organic Synthesis”, Butterworth 1987; ili
3. redukcijom spojeva formule (ΧΙ)
W-B2-Ar (ΧΙ)
gdje B2 ima gore navedeno značenje, sa spojevima formule ΧΙΙ
W-B3-Ar (ΧΙΙ)
gdje B3 predstavlja piperidine povezane u 1,4 položajima i odgovarajuće cikličke spojeve produljene s jednom metilenskom skupinom, ili
4. ciklizacijom spojeva formule ΧΙΙΙ
W-N-(C2H4Q)2 (ΧΙΙΙ)
u kojoj W i Q imaju gore opisano značenje, sa spojem formule ΧΙV
NH2-Ar (ΧΙV)
u kojoj Ar ima gore navedeno značenje, čime se dobiju spojevi formule (ΧV)
W-B1-Ar (ΧV)
Tvari formula ΙΙΙ i V, potrebne kao polazni materijali za sintezu novih spojeva, su poznate ili se mogu sintetizirati poznatim postupcima (npr. Organikum Barth Dt. Verl. der Wiss. 1993 ili A. R. Katritzky, C. W. Rees (ed.) Comprehensive Heterocyclic Chemistry Pergamon Press) iz analognih prekurzora.
Daljnja reakcija spojeva
H-B-Ar (ΙΙΙ)
proizvedenih kao u 1. do 4., u smislu slijedeće eliminacije bilo koje prisutne zaštitne skupine, da se dobiju spojevi formule V, odvija se povezivanjem sa spojevima formule ΧVΙ
Q-A-Qʹ (ΧVΙ)
u kojoj Q i Qʹ predstavljaju otpusne skupine, pod uvjetima koji su poznati samo po sebi.
Tvari formule ΙΙ, ΙV, VΙ i formula P-Ar, NH2-Ar, W-B1 i W-B2-p1, koje su potrebne kao polazni materijali za sintezu novih spojeva, su poznate ili se mogu sintetizirati iz analognih prekurzora postupcima opisanim u literaturi (npr. B. Dumaitre, , J. Med. Chem. 1996, 39. 1635 ili A. Yokoo et al., Bull. Chem. Soc. Jpn. 1956, 29, 631, ili L. Börjeson et al., Acta Chim. Scand. 1991, 45, 621 ili Organikum Barth Dt. Verl. der Wiss. 1993 ili A. R. Katritzky, C. W. Rees (ed.) Comprehensive Heterocyclic Chemistry Pergamon Press ili The Chemistry of Heterocyclic Compounds, J. Wiley & Sons inc. NY i literatura citirana u svakoj od tih publikacija).
Gore opisane reakcije odvijaju se općenito u inertnom organskom otapalu, npr. dimetilformamidu, acetonitrilu, diklormetanu, dimetil sulfoksidu, dimetoksietanu, toluenu, etil acetatu, ksilenu, ketonu kao što je aceton ili metil etil keton, alkoholu kao što je etanol ili n-butanol, ili cikličkom zasićenom eteru, npr. tetrahidrofuranu ili dioksanu.
Reakcije se općenito odvijaju pri 20°C do vrelišta otapala i općenito su gotove za 1 do 20 sati. potrebi, može biti prisutno sredstvo za vezanje kiseline, kao natrijev ili kalijev karbonat, natrijev metoksid, natrijev etoksid, natrijev hidrid, organometalni spojevi (butil-litij, alkilmagnezijevi spojevi), kalijev t-butoksid, piridin ili trietilenamin.
Tamo gdje je to prikladno, reakcije se odvijaju uz upotrebu katalizatora kao što su prijelazni metali i njihovi kompleksi, npr. Pd-C, Pd (PPh3)4, Pd (OAc)2, Pd (P (oTol)3)4, Pd2 (dba)3 ili Ni (COD)2.
Sirov proizvod izolira se na uobičajen način, na primjer filtracijom, odstranjivanjem otapala destilacijom ili ekstrakcijom iz reakcijske smjese.
spojevi formule I mogu se očistiti prekristalizacijom iz uobičajenih organskih otapala ili kromatografijom na stupcu.
Osim derivata 3-supstituiranog tetrahidropiridopirimidinona, izum također uključuje i kiselinske adicijske soli spojeva formule I s fiziološki podnošljivim kiselinama. Primjeri prikladnih fiziološki podnošljivih organskih i anorganskih kiselina jesu solna kiselina, bromovodična kiselina, fosforna kiselina, sumporna kiselina, oksalna kiselina, maleinska kiselina, fumarna kiselina, mliječna kiselina, vinska kiselina, adipinska kiselina ili benzojeva kiselina. Daljnje kiseline, koje se mogu upotrijebiti, opisane su u “Fortschritte der Arzneimittelforschung”, Vol. 10, str. 224 i dalje, Birkhäuser Verlag, Basel i Stuttgart, 1966.
Kiselinske adicijske soli proizvode se na uobičajen način miješanjem slobodne baze s odgovarajućom kiselinom, ako je prikladno u otopini u organskom otapalu, na primjer u nižem alkoholu kao što je metanol, etanol ili propanol, eteru, kao što je metil t-butil eter, ketonu kao što je aceton ili metil etil keton ili esteru kao što je etil acetat.
S tim u skladu izum se također odnosi na terapeutski sastav koji, pored uobičajenih nosača i sredstava za razrjeđivanje, kao aktivnu tvar sadrži spoj formule I ili njegovu farmakološki podnošljivu kiselinsku adicijsku sol, te na upotrebu novih spojeva za suzbijanje bolesti.
spojevi mogu se dati na uobičajen način oralno ili parenteralno, intravenski ili intramuskularno.
Doziranje ovisi o starosti, stanju i težini pacijenta, te o načinu davanja. U pravilu kod oralnog davanja dnevna doza aktivne tvari iznosi pribl. 1 do 100 mg/kg tjelesne težine i od 0,1 i 10 mg/kg tjelesne težine kod parenteralnog davanja.
spojevi mogu se primijeniti u uobičajenim krutim ili tekućim farmaceutskim oblicima, npr. kao neprevučene ili (s filmom) prevučene tablete, kapsule, puderi, granule, čepići, otopine, masti, kreme ili sprejevi. Oni se proizvode na uobičajen način. U tu svrhu se aktivne tvari mogu preraditi s uobičajenim farmaceutskim pomoćnim sredstvima kao što su veziva za tablete, punila, konzervansi, sredstva za dezintegraciju tableta, sredstva za regulaciju tečenja, omekšivači, sredstva za kvašenje, sredstva za dispergiranje, emulgatori, otapala, sredstva za usporavanje oslobađanja aktivne tvari, antioksidanti i/ili potisni plinovi (usporedi H. Sucker et al.: Pharmaceutische Technologie, Thieme Verlag, Stuttgart, 1978). Tako dobiveni oblici za davanje sadrže aktivnu tvar normalno količinom od 1 do 99 mas. %.
spojevi imaju visok afinitet za receptore serotonina 5-HT1B, 5-HT1D i 5-HT1A. Pri tome, afinitet za te receptore je otprilike jednake veličine, barem istog reda veličine. K tome, neki od novih spojeva pokazuju dobru inhibiciju ponovnog uzimanja serotonina, što je načelno prisutno kod većine antidepresanata.
Ti spojevi su prikladni kao lijekovi za liječenje patofizioloških stanja kod kojih je snižene koncentracija serotonina i kod kojih se u okviru terapije želi ciljano blokirati aktivnost presinaptičkih receptora 5-HT1B, 5-HT1A i 5-HT1D, a da se pri tome ne utječe jako na druge receptore. Takovo bolesno stanje je primjerice depresija.
Spojevi predloženog izuma mogu se također upotrijebiti i za liječenje poremećaja raspoloženja uvjetovanog središnjom nervozom, kao što su sezonski osjećajni poremećaji i distimije. Tu spadaju također i stanja straha, kao opći strah, napadi panike, sociofobija, opsesivno-kompulzivne neuroze i simptomi post-traumatskog stresa, poremećaji pamćenja uključujući demenciju, amneziju i gubitak pamćenja zbog starosti, kao i psihogene poremećaje uzimanja hrane kao što je neurotična anoreksija i neurotična bulimija.
Osim toga, spojevi prema izumu mogu se upotrijebiti za liječenje endokrilnih bolesti, kao hiperprolaktinemije i za liječenje vazospazmi (naročito moždanih krvnih žila), hipertenzije i gastrointestinalnih poremećaja koji su povezani s poremećajima motiliteta i sekrecije. Daljnje područje primjene su seksualni poremećaji.
Slijedeći primjeri služe za objašnjenje izuma, bez namjere njegovog ograničenja.
Primjer 1
3-[2-[4-(2-metoksifenil)-1-piperazinil]etil]-3,5,7,8-tetrahidro-4-okso-6-benzilpirido[4,3-d]pirimidin
Priprava polaznih materijala
a) 3,5,7,8- tetrahidro-4-okso-6-benzilpirido[4,3-d]pirimidin
4,7 g natrija reagira u malim obrocima s 250 ml etanola i zatim se pri 5-10°C doda kap po kap suspenziju od 14,2 g (0,05 mola) N-benzil-4-piridinon-3-karboksilata u etanolu. Miješa se 30 minuta i zatim se polako doda 6 g (0,075 mola) formamidin hidroklorida i reakcijsku smjesu se refluktira 10 sati. Otapalo se odstrani pod smanjenim tlakom i ostatak se u 100 ml vode namjesti s 2N solnom kiselinom na pH = 6,5 - 7, tako da se proizvod istaloži. Kristali se odsisaju i osuše u vakuumu. Na taj način izolirano je 8 g (66%). Talište 88°C.
Na isti način dobiveni su 3,5,7,8-tetrahidro-4-okso-6-benzilpirido[4,3-d]pirimidin (talište 199°C) i 1,1-dimetiletil 3,5,7,8-tetrahidro-4-okso-6-benzilpirido[4,3-d]pirimidin-6-karboksilat (talište 160°C).
b) 1-(2-metoksifenil)-4-(2-kloretil) piperazin
19,2 g (0,1 mola) o-metoksifenilpiprazina i 13,8 g (0,1 mola) kalijevog karbonata otopi se u 200 ml DMF-a pri sobnoj temperaturi i nakon 30 minuta doda se 30 ml (0,36 mola) i 1-brom-2-kloretana. Smjesu se miješa 2 sata pri sobnoj temperaturi. Prelije se na led-vodu i zatim se ekstrahira s metil terc. butil eterom, organsku fazu se ispere s vodom, osuši preko natrijevog sulfata i zatim zgusne. K otopini ostatka u etil acetatu doda se 30%-nu otopinu izopropanolne HCI da se istaloži hidroklorid, koji se odfiltrira i osuši u vakuumskoj sušilici pri 40°C. Dobiveno je 17 g (67%) tvari. Talište 200°C.
Na isti način dobiveni su 1-(2-metoksifenil)-4-(3-klorpropil) piperazin (talište 217°C, hidroklorid), 1-(3,4-dimetilfenil)-4-(2-kloretil) piperazin (talište 260°C, hidroklorid), 1-(2-pirimidil)-4-(2-kloretil) piperazin (talište 270°C, hidroklorid), 1-(1-naftil)-4-(3-klorpropil) piperazin (talište 217°C, hidroklorid).
Dolje su prikazana dva primjera sinteze piperazina.
1-(5-tetralinil) piperazin
14,7 g (0,1 mola) 5-aminotetralina i 18 g (0,11 mola) bis (β-kloretil) amin hidroklorida u 300 ml n-butanola refluktira se 48 sati i ohladi, doda se 5,4 g natrijevog karbonata i smjesu se refluktira daljnjih 20 sati. Talog dobiven nakon hlađenja se odsisa, preuzme u vodu i doda se 2N otopinu natrijevog hidroksida. Vodenu fazu se ekstrahira s etil acetatom, ispere s vodom, zatim se osuši preko natrijevog sulfata i zgusne pod smanjenim tlakom. Na taj način izolirano je 10,7 g (50%) proizvoda kao ulja.
4-(1-piperazinil) izokinolin
4,51 g (21,7 mmola) 4-brom izokinolina, 4,65 g (25,0 mmolova) t-butil piperazin-N-karboksilata, 0,1 g (0,11 mmola) tris (dibenzilidenaceton) dipaladija, 0,11 g (0,18 mmola) 2, 2ʹ-bis (difenilfosfino)-1,1ʹ-binaftila i 2,92 g (30,4 mmolova) natrijevog t-butoksida pomiješa se u 50 ml toluena i miješa se 2 sata pri 75°C. Reakcijsku smjesu se prelije na led/natrijev klorid i ekstrahira s etil acetatom. Organsku fazu se osuši preko natrijevog sulfata i otapalo se odstrani na rotacijskom isparivaču. Proizvod kristalizira, odfiltrira se odsisavanjem i ispere s pentanom. Dobiveno je 5,5 g (81%) Boc-zaštićenog piperazina (talište 111 °C). 5,2 g (16,6 mmolova) te tvari preuzme se u 17 ml diklormetana i pri 0°C polako se doda 17 ml (0,22 mola) trifluoroctene kiseline. Smjesu se miješa 4 sata pri 0°C, prelije se na led-vodu i ekstrahira s diklormetanom. Vodenu fazu se profiltrira, zaluži i ekstrahira s diklormetanom. Osuši se preko natrijevog sulfata i glavninu otapala se odstrani. Zatim se razrijedi s dietil eterom i hidroklorid se istaloži sa eterskom solnom kiselinom. Dobiveno je 3,2 g (67%) proizvoda. (Talište 293°C).
Istim postupcima kao što su dva gore opisana dobiveni su slijedeći spojevi: 1-(1-naftil) perhidroazepin (85°C, hidroklorid), 1-(1-naftilmetil) piperazepin (ulje), 4-(1-piperazinil) indan (ulje), 1-(1-naftil) piperazin (82°C), 4-klor-1-(1-piperazinil) ftalazin (205°C, raspadanje) i 4-(1- piperazinil) kinazolin (320°C, hidroklorid). Drugi derivati su komercijalno dostupni.
Pripravljenje krajnjeg proizvoda
2,9 g (10 mmolova) kloretilpiperazina [b)] i 2,8 g (20 mmolova) kalijevog karbonata doda se k otopini od 2,4 g (10 mmolova) tetrahidropiridopirimidina [a)] u 40 ml DMF-a. Nakon 2 sata reakcije pri 90°C smjesu se prelije na led-vodu i ekstrahira s etil acetatom. Organsku fazu se ispere sa zasićenom otopinom natrijevog klorida i osuši preko natrijevog sulfata. Otapalo se odstrani pod smanjenim tlakom. Zaostalo ulje se preuzme u aceton i hidroklorid se istaloži s izopropanolom/HCI. Dobiveno je 4 g (75%) proizvoda (talište 205°C).
NMR: CDCl3 δ 8,0 (s, 1H); 7,4-7,2 (m, 5H); 7,1-6,8 (m, 4H); 4,0 (t, 2H); 3,8 (s, 3H); 3,7 (s, 2H); 3,5 (s, 2H); 3,1 (široki s, 4H); 2,8-2,6 (m, 10H) ppm.
Slijedeći spojevi proizvedeni su sličnim putem:
Primjer 2
3-[2-[4-(2-metoksifenil)-1-piperazinil]etil]-3,5,7,8-tetrahidro-4-okso-6-benzilpirido[3,4-d]pirimidin (talište 181°C, hidroklorid).
Primjer 3
3-[3-[4-(2-metoksifenil)-1-piperazinil]propil]-3,5,7,8-tetrahidro-4-okso-6-benzilpirido[4,3-d]pirimidin (talište 198°C, hidroklorid).
Primjer 4
3-[3-[4-(2-metoksifenil)-1-piperazinil]propil]-3,5,7,8-tetrahidro-4-okso-6-benzilpirido[3,4-d]pirimidin (talište 190°C, hidroklorid).
Primjer 5
3-[3-[4-(2-metoksifenil)-1-piperazinil]-2-hidroksipropil]-3,5,7,8-tetrahidro-4-okso-6-benzilpirido[4,3-d] pirimidin.
Primjer 6
1,1-dimetiletil 3-[2-[4-(1-naftil)-1-piperazinil]etil]-3,5,7,8-tetrahidro-4-okso-6-pirido[4,3-d]pirimidin-6
-karboksilat (talište 170°C, hidroklorid).
Primjer 7
3-[2-[4-(4-izokinolinil)-1-piperazinil]etil]-3,5,7,8-tetrahidro-4-okso-6-benzilpirido[4,3-d]pirimidin (talište 268°C, hidroklorid).
Primjer 8
3-[2-[4-(1-naftil)-1-piperazinil]etil]-3,5,6,7,8-pentahidro-4-okso-6-pirido[4,3-d]pirimidin (talište 272°C,
hidroklorid).
Primjer 9
3-[2-[4-(4-kinazolinil)-1-piperazinil]etil]-3,5,7,8-tetrahidro-4-okso-6-benzilpirido[4,3-d]pirimidin (talište
258°C, hidroklorid).
Primjer 10
3-[2-[4-(1-naftil)-1-piperazinil]etil]-3,5,7,8-tetrahidro-4-okso-6-benzilpirido[4,3-d]pirimidin (talište 227°C,
hidroklorid).
Primjer 11
3-[2-[4-(1-naftil)-1,2,3,6-tetrahidro-1-piridinil]etil]-3,5,7,8-tetrahidro-4-okso-benzilpirido[4,3-d]pirimidin (talište
216°C, hidroklorid).
Sinteza polaznog materijala
a) N-Boc-4-(trifluormetansulfoniloksi)-1,2,3,6-tetrahidropiridin
Otopinu od 13,2 g (0,13 mola) diizopropilamina u 200 ml THF-a deprotnira se pri -78°C sa 100 ml nBuLi (1,6M u heksanu) i nakon 30 minuta pri toj temperaturi doda se kap po kap 20,0 g (0,1 mol) N-Boc-piperidona otopljenog u 50 ml THF-a. Nakon daljnja 3 sata pri -78°C doda se otopinu od 39,3 g (0,11 mola) N,N-bistrifluormetansulfonilanilina u 50 ml THF-a i smjesu se pusti da preko noći dosegne sobnu temperaturu. Za obradu se doda vodu, smjesu se ekstrahira s eterom, organsku fazu se ispere s NaHCO3 i vodom i osuši se preko natrijevog sulfata, otapalo se ispari. Sirov proizvod se očisti vakuumskom kromatografijom (silika gel, protočna faza heptan/etil acetat = 3/1).
Iskorištenje: 20,2 g (60% od teorijskog).
1H-NMR (270 MHz, CDCl3) δ = 1,4 (s, 9H); 2,4 (m, 2H); 3,6 (t, 2H); 4,1 (m, 2H); 5,8 (m, 1H) ppm.
b) N-Boc-4-(1-naftil)-1,2,3,6-tetrahidropiridin
22 ml 2M otopine natrijevog karbonata, 7,63 g (44,4 mmola) naftil-1-borne kiseline, 4,13 g (97,6 mmolova) litijevog klorida, 0,85 g (4,44 mmola) bakrenog (Ι) jodida i 2,1 g (1,77 mmola) tetrakistrifenilfosfin-paladija doda se uzastopce k 14,7 g (44,4 mmola) gore opisanog spoja otopljenog u 115 ml dimetoksietana i smjesu se kuha 4 sata. Za obradu doda se vodenu otopinu amonijaka, ekstrahira se s vodom i etil acetatom i nakon sušenja preko natrijevog sulfata, otapalo se ispari i ostatak se očisti vakuumskom kromatografijom (silika gel, protočna faza heptan/etil acetat = 4/1).
Iskorištenje: 8,2 g (57% od teorijskog).
1H-NMR (270 MHz, CDCl3) δ = 1,4 (s, 9H); 2,5 (m, 2H); 3,7 (t, 2H); 4,1 (m, 2H); 5,8 (m, 1H); 7,2-7,5 (m, 3H); 7,3-8,0 (m, 3H) ppm.
c) 4-(1-naftil) -1,2,3,6-tetrahidropiridin
7,84 g (25,3 mmolova) N-Boc-4-(1-naftil)-1,2,3,6-tetrahidropiridina miješa se preko noći s 200 ml eterske solne kiseline pri sobnoj temperaturi i istaloženi proizvod se odfiltrira.
Iskorištenje: 5,5 g (88% od teorijskog).
d) Pripravljenje krajnjeg proizvoda
0,61 g (2 mmola) 3-(2-kloretil)-3,5,7,8-tetrahidro-4-okso-benzilpirido[4,3-d]pirimidina i 2 ml (17 mmolova) trietilamina doda se k 0,51 g (2 mmola) 4-(1-naftil)-1,2,3,6-tetrahidropiridina otopljenog u 30 ml suhog DMF-a i smjesu se miješa 5 sati pri 120°C. Organsku fazu se razrijedi s eterom, ispere s vodom, osuši preko natrijevog sulfata i otapalo se odstrani pod smanjenim tlakom. Dobiveni sirov proizvod se očisti kromatografijom, čime se nakon taloženja soli s eterskom otopinom solne kiseline dobije bijelu krutu tvar.
Iskorištenje: 0,2 g (20% od teorijskog).
Talište: 237°C.
Primjer 12
3-[2-[4-(1-naftil)-1-piperidinil]etil]-3,5,7,8-tetrahidro-4-okso-benzilpirido[4,3-d]pirimidin
4-(1-naftil) piperidin
3,7 g (15,3 mmolova) 4-(1-naftil)-1,2,3,6-tetrahidropiridina otopi se u metanolu i nakon dodatka 0,8 g paladija na ugljenu hidrogenira se 48 sati pri sobnoj temperaturi. Katalizator se odfiltrira i otapalo se ispari.
Iskorištenje: 1,8 g (56% od teorijskog).
1H-NMR (270 MHz, CDCl3) δ = 1,6-1,8 (m, 2H); 2,0 (m, 2H); 2,9 (dt, 2H); 3,3 (d, 2H); 3,5 (tt, 1H); 7,4-7,6 (m, 4H); 7,7 (d, 1H); 7,9 (d, 1H); 8,1 (d, 1H) ppm.
Pripravljanje krajnjeg spoja
0,61 g (2 mmola) 3-(2-kloretil)-3,5,7,8-tetrahidro-4-okso-6-benzilpirido[4,3-d]pirimidina i 2 ml (17 mmolova) trietilamina doda se k 0,42 g (2 mmola) 4-(1-naftil)-piperidina otopljenog u 30 ml suhog DMF-a i smjesu se miješa 5 sati pri 120°C. Organsku fazu se razrijedi s eterom, ispere s vodom, osuši preko natrijevog sulfata i otapalo se odstrani pod smanjenim tlakom. Dobiveni sirov proizvod se očisti kromatografijom, čime se nakon taloženja soli s eterskom otopinom solne kiseline dobije bijelu krutu tvar.
Iskorištenje: 0,24 g (27% od teorijskog).
1H-NMR (270 MHz, CDCl3) δ = 8,3 (s, 1H); 8,0 (d, 1H); 7,8 (d, 1H); 7,7 (t, 1H); 7,5-7,2 (m, 9H); 4,5 (s, 2H); 4,0 (s, 2H); 3,7-2,3 (m, 15H); 2,1 (d, 2H) ppm.
Daljnji prednosni spojevi formule Ι navedeni su u slijedećoj tablici.
(F)
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
Claims (7)
1. Derivat 3-supstituiranog tetrahidropiridopirimidinona formule Ι
[image]
naznačen time, da
jedan od dva radikala X i Y je CH2, a drugi je NR1,
R1je vodik, razgranati ili nerazgranati C1-C6-alkil, CO-( C1-C4)-alkil, CO2tBu, Co-aril i radikal fenilalkil C1-C4 koji sa svoje strane može biti supstituiran na aromatskom sistemu s F, CI, Br, J, C1-C4-alkilom, C1-C4-alkoksi, trifluormetilom, hidroksilom, amino, cijano ili nitro,
A je razgranati ili nerazgranati (C1-C10)-alkilen ili ravan ili razgranati (C2-C10)-alkilen koji sadrži najmanje jednu skupinu Z odabranu između O, S, NR2, ciklopropila, CO2, CHOH, dvostruke ili trostruke veze,
R2je vodik ili C1-C4-alkil,
B je 1,4-piperidinilen, 1,2,3,6-tetrahidro-1,4-piridinilen, 1,4-piperazinilen ili odgovarajući ciklički spoj produljen s jednom metilenskom skupinom, pri čemu se povezivanje na A vrši preko dušikovog atoma skupine B, i
Ar je fenil koji nije supstituiran ili je supstituiran s razgranatim ili nerazgranatim (C1-C6)-alkilom, s razgranatim ili nerazgranatim O-(C1-C6)-alkilom, OH, F, CI, Br, J, trifluormetilom, NR22, CO2 R2, cijano ili fenilom, ili je tetralinil, indanil, fuzionirani aromatski sistemi kao naftil koji nije supstituiran ili je supstituiran sa (C1-C4)-alkilom ili O-(C1-C4)-alkilom, antril ili petero- ili šesteročlani aromatski heterocikl koji ima 1 ili 2 heteroatoma odabrana međusobno neovisno između O i N, koji također može biti fuzioniran na druge aromatske radikale,
i njegove soli s fiziološki podnošljivim kiselinama.
2. Derivat 3-supstituiranog tetrahidropiridopirimidinona prema zahtjevu 1, naznačen time, da
jedan od dva radikala X i Y je CH2, a drugi je NR1,
R1je vodik, razgranati ili nerazgranati C1-C4-alkil, CO-(C1-C4)-alkil, CO2tBu, COPh i radikal fenilalkil C1-C2 koji sa svoje strane može biti supstituiran na aromatskom sistemu s F, CI, Br, J, C1-C4-alkilom, C1-C4-alkoksi, trifluormetilom, hidroksilom ili cijano,
A je razgranati ili nerazgranati (C2-C5)-alkilen ili (C2-C5)-alkilen koji sadrži skupinu Z odabranu između CHOH, ciklopropila, dvostruke ili trostruke veze,
B je 1,4-piperidinilen, 1,2,3,6-tetrahidro-1,4-piridinilen, 1,4-piperazinilen ili homopiperazinilen, pri čemu se povezivanje na A vrši preko dušikovog atoma skupine B, i
Ar je fenil koji nije supstituiran ili je supstituiran s razgranatim ili nerazgranatim (C1-C6)-alkilom, s razgranatim ili nerazgranatim O-(C1-C6)-alkilom, F, CI, Br, J, trifluormetilom, NR22, CO2 R2, cijano ili fenilom, ili je tetralinil, indanil, fuzionirani aromatski sistemi kao naftil koji nije supstituiran ili je supstituiran sa (C1-C4)-alkilom ili O-(C1-C4)-alkilom, ili petero- ili šesteročlani aromatski heterocikl koji ima 1 ili 2 dušikova atoma, koji može biti fuzioniran na druge aromatske radikale.
3. Derivat 3-supstituiranog tetrahidropiridopirimidinona formule Ι prema zahtjevu 1, naznačen time, da
jedan od dva radikala X i Y je CH2, a drugi je NR1,
R1je vodik, C1-C2-alkil, CO-(C1-C4)-alkil ili radikal fenilalkilni C1-C2,
A je (C2-C3)-alkil,
B je 1,4-piperidinilen, 1,4-piperazinilen ili 1,2,3,6-tetrahidro-1,4-piridinilen i
Ar je pirimidinil, fenil koji nije supstituiran ili je supstituiran s O-(C1-C2)-alkilom u orto položaju, tetralinil, indanil ili naftil koji nije supstituiran ili je supstituiran sa (C1-C4)-alkilom ili O-(C1-C4)-alkilom.
4. Upotreba spojeva prema zahtjevima 1 - 3, naznačena time, da se oni koriste za proizvodnju lijekova.
5. Upotreba prema zahtjevu 4, naznačena time, da se oni koriste za liječenje depresije i srodnih zdravstvenih poremećaja.
6. Upotreba spojeva prema zahtjevima 1 - 3, naznačena time, da se oni koriste kao selektivni 5-HT1B i 5-HT1A antagonisti.
7. Upotreba prema zahtjevu 5, naznačena time, da se selektivni serotonin antagonizam nadopunjuje inhibicijom ponovnog uzimanja serotonina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19747063A DE19747063A1 (de) | 1997-10-24 | 1997-10-24 | 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP980554A2 true HRP980554A2 (en) | 1999-08-31 |
Family
ID=7846539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR19747063.7A HRP980554A2 (en) | 1997-10-24 | 1998-10-21 | 3-substituted tetrahydropyridopyrimidinon derivatives, their preparation and use |
Country Status (27)
Country | Link |
---|---|
US (1) | US6414157B1 (hr) |
EP (1) | EP1025100B1 (hr) |
JP (1) | JP2001521035A (hr) |
KR (1) | KR20010015787A (hr) |
CN (1) | CN1277611A (hr) |
AR (1) | AR015466A1 (hr) |
AT (1) | ATE212346T1 (hr) |
AU (1) | AU748666B2 (hr) |
BG (1) | BG104291A (hr) |
BR (1) | BR9812970A (hr) |
CA (1) | CA2305258A1 (hr) |
CO (1) | CO4980862A1 (hr) |
DE (2) | DE19747063A1 (hr) |
DK (1) | DK1025100T3 (hr) |
ES (1) | ES2172222T3 (hr) |
HR (1) | HRP980554A2 (hr) |
HU (1) | HUP0004648A3 (hr) |
ID (1) | ID24633A (hr) |
NO (1) | NO20001934L (hr) |
NZ (1) | NZ503486A (hr) |
PL (1) | PL340034A1 (hr) |
PT (1) | PT1025100E (hr) |
SK (1) | SK3872000A3 (hr) |
TR (1) | TR200001102T2 (hr) |
TW (1) | TW432063B (hr) |
WO (1) | WO1999021857A1 (hr) |
ZA (1) | ZA989664B (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19900544A1 (de) * | 1999-01-11 | 2000-07-13 | Basf Ag | Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie |
WO2004014909A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
ES2350977T3 (es) | 2002-11-05 | 2011-01-28 | Glaxo Group Limited | Agentes antibacterianos. |
CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
DE102004020908A1 (de) * | 2004-04-28 | 2005-11-17 | Grünenthal GmbH | Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen |
BRPI0607918A2 (pt) * | 2005-04-01 | 2009-10-20 | Warner Lambert Co | tetraidro-piridoazepin-8-onas e compostos relacionados para o tratemento da esquizofrenia. |
US8097610B2 (en) * | 2005-08-26 | 2012-01-17 | Shionogi & Co., Ltd. | Derivative having PPAR agonistic activity |
CN102952129B (zh) * | 2011-08-16 | 2015-09-23 | 上海师范大学 | 四氢吡啶并二氢嘧啶酮衍生物及其制备方法和应用 |
JP2023548031A (ja) | 2020-10-21 | 2023-11-15 | アリゴス セラピューティクス インコーポレイテッド | 二環式化合物 |
WO2022266193A1 (en) | 2021-06-18 | 2022-12-22 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0827149A (ja) * | 1994-07-08 | 1996-01-30 | Meiji Seika Kaisha Ltd | ピリミジノン誘導体およびその塩 |
-
1997
- 1997-10-24 DE DE19747063A patent/DE19747063A1/de not_active Withdrawn
-
1998
- 1998-10-05 AU AU97484/98A patent/AU748666B2/en not_active Ceased
- 1998-10-05 ID IDW20000762D patent/ID24633A/id unknown
- 1998-10-05 CN CN98810525A patent/CN1277611A/zh active Pending
- 1998-10-05 SK SK387-2000A patent/SK3872000A3/sk unknown
- 1998-10-05 HU HU0004648A patent/HUP0004648A3/hu unknown
- 1998-10-05 PT PT98951491T patent/PT1025100E/pt unknown
- 1998-10-05 DK DK98951491T patent/DK1025100T3/da active
- 1998-10-05 WO PCT/EP1998/006305 patent/WO1999021857A1/de not_active Application Discontinuation
- 1998-10-05 ES ES98951491T patent/ES2172222T3/es not_active Expired - Lifetime
- 1998-10-05 PL PL98340034A patent/PL340034A1/xx unknown
- 1998-10-05 TR TR2000/01102T patent/TR200001102T2/xx unknown
- 1998-10-05 AT AT98951491T patent/ATE212346T1/de not_active IP Right Cessation
- 1998-10-05 EP EP98951491A patent/EP1025100B1/de not_active Expired - Lifetime
- 1998-10-05 CA CA002305258A patent/CA2305258A1/en not_active Abandoned
- 1998-10-05 DE DE59802922T patent/DE59802922D1/de not_active Expired - Fee Related
- 1998-10-05 KR KR1020007004362A patent/KR20010015787A/ko not_active Application Discontinuation
- 1998-10-05 JP JP2000517967A patent/JP2001521035A/ja active Pending
- 1998-10-05 NZ NZ503486A patent/NZ503486A/en unknown
- 1998-10-05 BR BR9812970-8A patent/BR9812970A/pt not_active IP Right Cessation
- 1998-10-20 TW TW087117332A patent/TW432063B/zh not_active IP Right Cessation
- 1998-10-21 HR HR19747063.7A patent/HRP980554A2/hr not_active Application Discontinuation
- 1998-10-22 CO CO98061508A patent/CO4980862A1/es unknown
- 1998-10-23 ZA ZA9809664A patent/ZA989664B/xx unknown
- 1998-10-23 AR ARP980105297A patent/AR015466A1/es not_active Application Discontinuation
-
2000
- 2000-04-03 BG BG104291A patent/BG104291A/xx unknown
- 2000-04-10 US US09/529,231 patent/US6414157B1/en not_active Expired - Lifetime
- 2000-04-13 NO NO20001934A patent/NO20001934L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20010015787A (ko) | 2001-02-26 |
AU748666B2 (en) | 2002-06-06 |
PT1025100E (pt) | 2002-07-31 |
CA2305258A1 (en) | 1999-05-06 |
HUP0004648A3 (en) | 2001-11-28 |
EP1025100A1 (de) | 2000-08-09 |
JP2001521035A (ja) | 2001-11-06 |
EP1025100B1 (de) | 2002-01-23 |
TR200001102T2 (tr) | 2000-08-21 |
SK3872000A3 (en) | 2000-09-12 |
PL340034A1 (en) | 2001-01-15 |
NO20001934D0 (no) | 2000-04-13 |
ID24633A (id) | 2000-07-27 |
ES2172222T3 (es) | 2002-09-16 |
NO20001934L (no) | 2000-04-13 |
DE19747063A1 (de) | 1999-04-29 |
ATE212346T1 (de) | 2002-02-15 |
CO4980862A1 (es) | 2000-11-27 |
US6414157B1 (en) | 2002-07-02 |
DE59802922D1 (de) | 2002-03-14 |
NZ503486A (en) | 2001-04-27 |
CN1277611A (zh) | 2000-12-20 |
BR9812970A (pt) | 2000-08-08 |
HUP0004648A2 (hu) | 2001-05-28 |
WO1999021857A1 (de) | 1999-05-06 |
ZA989664B (en) | 2000-04-25 |
TW432063B (en) | 2001-05-01 |
AU9748498A (en) | 1999-05-17 |
DK1025100T3 (da) | 2002-05-06 |
AR015466A1 (es) | 2001-05-02 |
BG104291A (en) | 2001-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4572195B2 (ja) | 8−置換−6,7,8,9−テトラヒドロピリミド[1,2−a]ピリミジン−4−オン誘導体 | |
HRP980319A2 (en) | 3-substituted 3,4-dihydro-thieno/2,3-d/pyrimidine derivatives, their preparation and use | |
CZ281676B6 (cs) | 1-piperazin-1,2-dihydroindenové deriváty, farmaceutické prostředky s jejich obsahem a použití uvedených látek pro výrobu farmaceutických prostředků | |
HRP980554A2 (en) | 3-substituted tetrahydropyridopyrimidinon derivatives, their preparation and use | |
HRP980555A2 (en) | 2-substituted 1,2-benzoisothiazole derivatives, their preparation and use | |
KR20010022658A (ko) | 3-치환된 3,4,5,7-테트라히드로-피롤로[3'4':4,5]티에노[2,3-d]피리미딘 유도체, 그의 제법 및 5ht길항제로서의 용도 | |
EP1023296A1 (de) | 3-SUBSTITUIERTE PYRIDO 3',4':4,5] THIENO 2,3-d] PYRIMIDIN-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG | |
EP1140099A1 (de) | Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie | |
MXPA00002601A (en) | 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use | |
CZ20001454A3 (cs) | Deriváty 3-substituovaného tetrahydropyridopyrimidinonu, způsob jejich přípravy a použití | |
MXPA00003136A (en) | 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d) | |
CZ20001436A3 (cs) | Disubstituované deriváty 1,2-benzisotiazolu a jejich použití |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
OBST | Application withdrawn |